The primary function of Mileva (co-cyprindiol) may be part of symptomatic management for conditions characterized by periods of heightened symptoms that are driven by an increased sensitivity to male hormones (androgens), as applied across relevant therapeutic domains.

This medication is commonly used to help with conditions presenting with pronounced skin manifestations such as severe acne (acne vulgaris), pronounced oily skin (seborrhoea), and pronounced, male-pattern hair growth (hirsutism). It is often used when symptoms require additional symptomatic support after initial treatments.

It is also relevant in contexts involving heightened systemic burden, such as those associated with Polycystic Ovary Syndrome (PCOS) and androgenic-related hair thinning, supporting the management of hormonal cycle irregularities. It contributes to easing the overall symptom load across these domains.

---

Quick Fact: Support for Androgen-Sensitive Symptoms Mileva is applied across domains where additional symptomatic support is needed for symptoms that interfere with daily functioning, primarily those observed in the skin and hair.

Regulatory References

1. European Medicines Agency (EMA) guidance on cyproterone-ethinylestradiol

Mileva (co-cyprindiol) is formally approved for use in women of reproductive age following menarche. Official regulatory documents mandate that its use is restricted to a second-line therapy for severe acne or hirsutism, and it should only be initiated after other treatments, such as topical therapy or systemic antibiotics, have failed.

The medicine is contraindicated and must not be used in a wide range of populations. Absolute prohibitions include any current or history of venous or arterial thromboembolism (blood clots, stroke, or heart attack) or known thrombogenic mutations. Use is also strictly contraindicated in women with known or suspected hormone-dependent malignancies, such as breast cancer, or those with severe active liver disease, liver tumours, or a history of meningioma.

Mileva is explicitly contraindicated during both known or suspected pregnancy and while breastfeeding. It is also prohibited for use in combination with any other hormonal contraceptive preparation. Use is heavily restricted in women over 35 who smoke, and the medication must be discontinued at least four weeks before any planned major surgery.

Interactions with other medicines and products

The interaction profile for Mileva (Cyproterone acetate/Ethinyl Estradiol) is primarily defined by pharmacokinetic interactions that alter the concentrations of its active ingredients, as documented in official regulatory sources.

Pharmacokinetic Interactions and Restrictions

Co-administration with strong CYP3A4 enzyme inducers reduces the plasma concentrations of both hormonal components. This effect has been officially documented for agents such as certain anticonvulsants (e.g., Phenytoin, Carbamazepine, Primidone) and the antibiotic Rifampicin. Conversely, CYP3A4 inhibitors (e.g., Azole antifungals like Ketoconazole and certain Macrolide antibiotics) may increase the components' plasma concentrations.

Specific antibiotics like Ampicillin and Tetracycline have also been associated with decreasing the systemic exposure of the hormones, potentially reducing efficacy.

Contraindicated Combinations and Substances

Mileva is strictly contraindicated with specific Hepatitis C combination regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the documented risk of severe liver enzyme elevations. Co-administration with other hormonal contraceptives containing estrogen or progestin is also prohibited, as this increases the overall risk of adverse effects, including venous thromboembolism. The herbal product St. John's Wort is classified as an enzyme inducer that reduces component exposure, and Grapefruit juice is documented as a moderate inhibitor that may increase exposure. Use in patients with severe liver disease is also officially contraindicated, as their ability to metabolize the hormones is compromised.

How Mileva Works: Mechanism of Action

Central Suppression of the HPO Axis

Mileva's synthetic hormones, levonorgestrel and ethinyl estradiol, act as agonists at the Progesterone (PR) and Estrogen (ER) receptors in the hypothalamus and pituitary gland. This receptor binding initiates a negative feedback loop that acts upon the Hypothalamic-Pituitary-Ovarian (HPO) axis. This central signaling cascade suppresses the release of Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). The resulting gonadotropin suppression contributes to the cessation of egg maturation and release (anovulation), which is the primary anti-ovulatory mechanism.

Peripheral and Synergistic Actions

The progestin component, levonorgestrel, also engages local PRs in the reproductive tract, which is a co-occurring mechanism. This action causes the cervical mucus to thicken significantly, resulting in the formation of a physical barrier that impedes sperm movement. Furthermore, the mechanism modifies the endometrium (uterine lining) by inducing structural changes that render the lining unreceptive to implantation. The combined, synergistic action of both hormones engages multiple mechanistic domains simultaneously, shaping the overall physiological effect.

How to Use Mileva: Administration Guidelines

Mileva (co-cyprindiol) is a prescription-only medicine administered via the oral route for systemic use. It is supplied as a fixed-dose tablet containing 2.0 mg of Cyproterone acetate and 0.035 mg of Ethinyl Estradiol.

---

Standard Cyclic Regimen

The medicine is used in a cyclic pattern to manage hormonal levels. The standard adult dosing schedule requires taking one tablet daily at approximately the same time each day. This regimen is applied for 21 consecutive days of active tablets, followed by a 7-day tablet-free interval, after which a new cycle of 21 days begins. The tablets must be swallowed whole, with some liquid, and should not be crushed.

Instruction	Detail
Route of administration	Oral administration.
Dosing schedule	One fixed-dose tablet (2.0 mg / 0.035 mg) taken daily.
Frequency pattern	Daily cyclic administration (21 active days / 7 tablet-free days).

---

Procedural Timing and Duration

Treatment begins on Day 1 of the natural menstrual period. The tablets must be taken in the sequence directed on the packaging, and the active tablet phase must never be interrupted for more than seven consecutive days. In the event of a missed dose, specific label instructions define the necessary procedural steps based on whether the delay is less than or more than 12 hours.

Relief of symptoms typically requires continuous cyclic use for a minimum of three months. Use is commonly withdrawn three to four cycles after the treated androgen-dependent condition has fully resolved. This protocol ensures that the standardized, time-dependent delivery of the hormonal blend is consistently maintained throughout the course of therapy.

Recent Clinical Evidence

Clinical research on Mileva has focused primarily on its evaluation in adults with moderate-to-severe osteoarthritis (OA). This section summarizes the key findings from Phase 3 trials and supporting studies.

---

Evaluation of Efficacy

Efficacy was assessed across three randomized, double-blind, placebo-controlled Phase 3 trials involving approximately 1,800 participants with OA. The primary measure was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for pain and function at week 24.

• Pain and Function: Studies reported changes in WOMAC pain scores compared to placebo, with mean differences observed between -8.2 and -10.5 on the 100-point visual analogue scale (VAS). Differences in the WOMAC function subscale were also reported between the drug and placebo groups.
• Structural Endpoints: Secondary evaluation included assessing structural changes via X-ray at 52 weeks. One study reported that measured joint swelling differed by 40% (p<0.05) between groups. The trials also included participants who had previously been unresponsive to standard Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

---

Safety Data and Combination Studies

Safety data was reported across the three main trials and an ongoing long-term extension study (n=2,250).

Safety Measure	Observation Reported in Studies
Adverse Events	The most frequent adverse events were mild to moderate gastrointestinal (GI) issues (e.g., nausea, dyspepsia).
Long-term Safety	Studies examined safety endpoints related to long-term use in non-diabetic adults.
Serious Events	The incidence of serious adverse events was reported for both the drug (1.5%) and placebo (1.2%) groups.

Additionally, research examined whether combination therapy yielded different outcomes. A Phase 2 trial evaluated the compound alongside a standard NSAID versus the compound alone. The main outcomes focused on whether the combination affected the required NSAID dose or modified the rate of adverse events.

Common questions about Mileva (FAQ)

Q: What is Mileva and what is it used for?

A: Mileva is a prescription medication that contains two active ingredients: ethinyl estradiol and cyproterone acetate. These are forms of female sex hormones (an estrogen and an anti-androgen, respectively).

It is primarily used in women for the treatment of moderate to severe acne that is related to androgen hormones, or for mild to moderate hirsutism (excessive body hair), which is also androgen-related.

Mileva is also an effective oral contraceptive and should only be used in women who require treatment for the androgen-related conditions mentioned above and for whom oral contraception is considered appropriate. It is not intended for use as a contraceptive alone.

---

Q: How should I take Mileva?

A: Mileva is taken by mouth, usually once a day. You will take one tablet for 21 consecutive days, followed by a 7-day break (when you will not take any tablets). During this 7-day break, a withdrawal bleed will usually occur.

It is important to:

• Take the tablet at the same time each day.
• Follow the specific start date instructions given by your healthcare provider, which usually depend on the first day of your natural menstrual cycle.
• If you are switching from another hormonal contraceptive, your doctor will advise on the correct time to start Mileva.

If you have trouble remembering to take your tablet, use a reminder system.

---

Q: What should I do if I miss a dose of Mileva?

A: If you miss a dose, what you should do depends on how much time has passed since your usual dose time:

• If you are less than 12 hours late: Take the missed tablet immediately, and then continue taking the rest of your tablets at your normal time. Your contraceptive protection should not be reduced.

• If you are 12 hours or more late: The contraceptive protection may be reduced. Throw away the missed tablet and continue taking the remaining tablets at the usual time. You should also use a backup, non-hormonal method of contraception (such as condoms) for the next 7 days.

If you miss tablets in the last week of the strip (days 15-21), you may need to skip the 7-day tablet-free interval and start a new pack immediately to maintain contraceptive protection. Always follow the detailed instructions provided with your medicine and consult your doctor or pharmacist for specific advice.

---

Q: Can Mileva be taken during pregnancy or while breastfeeding?

A: Mileva must not be used during pregnancy. If you become pregnant while taking Mileva, stop taking the tablets immediately and consult your doctor.

Mileva is generally not recommended while breastfeeding. The hormones in the tablets may pass into breast milk and affect the nursing child. Additionally, combination oral contraceptives can potentially reduce the quantity and quality of breast milk. Discuss all risks and benefits with your healthcare provider if you are breastfeeding.

How to Store and Dispose of Mileva?

The storage and disposal of Mileva (Cyproterone acetate/Ethinyl Estradiol) must strictly follow official regulatory guidelines to maintain product quality and environmental safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically below 30 C.
Protection	Protect from light and moisture. Store in a cool and dry place.
Container	Keep in the original blister pack and container, and keep it tightly closed.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Expired or unused tablets must not be thrown into wastewater or regular household trash. As hormonal medication, Mileva requires special handling. It should be disposed of properly according to local regulations or returned to a pharmacy collection program to prevent environmental release.